Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Atorvastatin 40mg Versus Rosuvastatin 20mg in Type II Diabetic Patients With Previous Acute Coronary Syndrome : Randomized Clinical Trial

NCT05306990 is registered in ClinicalTrials.gov with Helwan University as lead sponsor.

NCT NCT05306990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05306990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Atorvastatin 40mg Versus Rosuvastatin 20mg in Type II Diabetic Patients With Previous Acute Coronary Syndrome : Randomized Clinical Trial
Lead sponsor
Helwan University
Phase
Not applicable
Overall status
Completed
Start date
April 20, 2017
Completion date
January 31, 2021
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, hydroxymethylglutaryl-coa reductase inhibitors